Maples Group Advises Basel Medical Group on US$8.8 Million Public Offering

Maples and Calder, the Maples Group’s law firm, is pleased to have advised Singapore-based clinical services provider Basel Medical Group Ltd (“Basel”) on its NASDAQ initial public offering (“IPO”) valued at US$8.8 million. Shortly after closing, the over-allotment option was exercised in full raising an additional US$1.32 million.

The firm’s BVI office managing partner Chris Newton along with Corporate Associates Chloe Harris and Elliot Ruffle provided BVI Corporate advice to Basel.

The multi-jurisdictional transaction spanned across Singapore, New York and the BVI and is the first Singapore-based med-tech IPO on the NASDAQ for 2025. The net proceeds of the IPO and over-allotment will be used for Basel’s future business expansions in Singapore and Southeast Asia as well as daily operations and working capital.

“We are proud to have provided Basel with the BVI counsel necessary to help them achieve this significant milestone and we look forward to seeing the positive impact the IPO has on their business expansions and operations.” Commented Chris Newton. “This transaction underscores the strength and expertise of our team to provide strong BVI counsel to our clients looking to access the US public markets.”

Basel Medical Group Ltd is a Singapore-based clinical provider of general and subspecialised orthopaedic and trauma services, sports medicine and surgery, orthopaedic procedures, as well as neurosurgical treatments across Singapore and Southeast Asia.